Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODI-2001 Vaccine in Metastatic or Locally Advanced Colorectal or Pancreatic Cancer
NCT07587827Phase 1Not yet recruiting
- Sponsor
- Centre Georges-François Leclerc
- Start
- Nov 2026
- Primary completion
- May 2027
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ODI-2001 in colorectal cancer (CRC) and pancreatic cancer (PC) (3 arms), sponsored by Centre Georges-François Leclerc. Primary endpoints: Maximum Tolerated Dose at 28 days and Progression-Free Survival at 14 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ODI-2001
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07587827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587827.